Bullish & Foolish
Full ZNTL fundamentals All 466 on the Survival Watch

ZNTLZentalis Pharmaceuticals, Inc.

Is Zentalis Pharmaceuticals struggling financially?

Yes, by its own account. Zentalis Pharmaceuticals told the SEC on 12 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

15/100

Critical

Sector
Biotech/Pharma
Market cap
$362.1M
Source filing
10-Q 12 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 2months

    If the burn speeds up

    Empty by Aug 2026

  • 3months

    If it eases off

    Empty by Sep 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$24.8M

÷

Cash burned over the last 12 months

$125.2M

What Zentalis Pharmaceuticals told the SEC

…unless and until it successfully completes clinical development, obtains regulatory approval for, and commercializes one or more of its product candidates. Substantial doubt about an entity’s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within…

Zentalis Pharmaceuticals, Inc., Form 10-Q, filed 12 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • Cash burn is narrowing It is spending 54% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt